New tool predicts liver metastasis risks in neuroendocrine tumors

A novel Liver Metastasis Score (LMS) effectively predicts liver metastasis risk for patients with gastroenteropancreatic neuroendocrine tumors (GEP-NETs) post-surgery. Among 724 patients studied, 9.1% developed liver metastasis, significantly impacting survival rates (63.6% vs. 95.8% for no metastasis). Key risk factors identified include Ki-67 index, vascular invasion, lymph node metastases, and absence of adjuvant therapy. The LMS, validated with strong discrimination, segments patients into low, intermediate, and high-risk categories to guide targeted management.